Compare · AYTU vs ZVRA
AYTU vs ZVRA
Side-by-side comparison of Aytu BioPharma Inc. (AYTU) and Zevra Therapeutics Inc. (ZVRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AYTU and ZVRA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ZVRA is the larger of the two at $552.2M, about 19.1x AYTU ($28.9M).
- AYTU has been more active in the news (11 items in the past 4 weeks vs 6 for ZVRA).
- ZVRA has more recent analyst coverage (9 ratings vs 3 for AYTU).
- Company
- Aytu BioPharma Inc.
- Zevra Therapeutics Inc.
- Price
- -
- -
- Market cap
- $28.9M
- $552.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 11
- 6
- Recent ratings
- 3
- 9
Aytu BioPharma Inc.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Latest AYTU
- Aytu BioScience downgraded by Lake Street with a new price target
- SEC Form 10-Q filed by Aytu BioPharma Inc.
- SEC Form 425 filed by Aytu BioPharma Inc.
- Aytu BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results
- Rosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansion
- Aytu BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Rosemont Pharmaceuticals to Acquire Aytu BioPharma in All-Cash Tender Offer
- Aytu BioPharma to Report Fiscal 2027 First Quarter Operational and Financial Results on November 16, 2026
- FDA Approval for ZOLPIMIST issued to AYTU
Latest ZVRA
- Zevra Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
- Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
- Amendment: SEC Form SCHEDULE 13G/A filed by Zevra Therapeutics Inc.
- SEC Form 10-Q filed by Zevra Therapeutics Inc.
- Zevra Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Zevra Reports Third Quarter 2026 Financial Results and Corporate Update
- Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call
- President and CEO Mcfarlane Neil F. sold $224,948 worth of shares (20,000 units at $11.25) as part of a pre-agreed trading plan (SEC Form 4)
- Zevra Therapeutics to Present at Upcoming Investor Conferences
- Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium